NCT02936102View on ClinicalTrials.gov

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

PHASE1TerminatedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

November 22, 2024

Study Completion Date

November 22, 2024

Conditions
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Interventions
DRUG

FAZ053

Anti-PD-L1 Antibody

DRUG

PDR001

Anti-PD-1 Antibody

Trial Locations (12)

10002

Novartis Investigative Site, Taipei

10065

Memorial Sloan Kettering Cancer Ctr, New York

20133

Novartis Investigative Site, Milan

31059

Novartis Investigative Site, Toulouse

41013

Novartis Investigative Site, Seville

41124

Novartis Investigative Site, Modena

77030

UT MD Anderson Cancer Center, Houston

119074

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

M5G 2M9

Novartis Investigative Site, Toronto

135 8550

Novartis Investigative Site, Koto Ku

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY